Novartis Gleevec Label Updated With Cardiovascular Risk Language
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Revised labeling for Novartis'Gleevec (imatinib) advises that patients taking the medication who have cardiac disease or are at risk for cardiac failure should be closely monitored